

First author	Number resected	Complete resection (%)	Incomplete Resection margins	Number Malignant (%)	Tumour diameter average (cm)	Tumour diameter (range, cm)	Malignancy criteria
Boddeart	80/80 (100%)	76/79 (96%)	R1 – bSFTP(1), R1 - mSFTP(2, 1 recurred)	28/79 (35%)	7.6 ^(MN) ± 4.9 ^(SD)	-	England (1989)
Bylicki	64/68 (94%)	57/64 (89%)	R1 – SFTP (5) R2 – SFTP (2)	39/68 (57%)	9	2.8 – 25	England (1989)
Cardillo	110/110 (100%)	100%	All R0	15/110 (13.6%)	8.5	0.4 – 28	England (1989)
Chu	39/40 (97.5%)	100%	-	7/39 (18%)	Tumour <10cm in 24/40 cases	-	-
Demicco (2012)	29/31 (93.5%)	-	Mixed data	-	15 ^(MD)	1 – 30	-
Demicco (2017)	36/36 (100%)	-	Mixed data	-	5.8 ^(MD)	1 – 23	-
DeVito	27/28 (96.4%)	23/24 (95.8%)	R1 – bSFTP (1) No recurrence	13/28 (46.4%)	Tumour <10cm in 17/27 cases	-	England (1989) & World Health Organisation (2013)
England	216/223 (96.8%)	-		82/223 (36.8%)	62% >10cm	1-39	England (1989)
Enon	25/25 (100%) Benign	100%	All surgical margins clear	3/28 (10.7%)	bSFTP 8.7 ^(MN)	3 – 22	Increased cellularity with crowding and overlapping nuclei, nuclear pleomorphism, and a high mitotic activity (>4 mitosis/ 10HPF).
Franzen	42/42 (100%)	100%	All R0	18/42 (42.9%)	6.2 ^(MD)	4.8 - 14.1	One or more of: high cellularity, high mitotic activity (>4 mitosis/ 10 HPF) or pleomorphism.
Gholami	67/67 (100%)	-	Mixed data	Mixed data	Mixed data	-	Four or greater mitoses per HPF
Guo	39/39 (100%)	100%	All surgical margins clear	4/39 (10.3%)	7.71 ^(MN) ± 4.78 ^(SD)	-	England (1989)
Gupta	28/28 (100%)	-	-	10/28 (36%)	bSFTP 6.05 ^(MD) mSFTP 15.7 ^(MD)	-	World Health Organisation (2013)
Harrison–Phipps	84/84 (100%)	100%	-	11/84 (13%)	bSFTP 4.5 ^(MD) mSFTP 12.0 ^(MD)	-	>4 mitosis/10HPF seen on light microscopic analysis

Helage	56/56 (100%)	100%	All R0	23/56 (41%)	bSFTP 7.5 ^(MN) mSFTP 12.4 ^(MN)	-	England (1989)
Kim	40/40 (100%)	-	-	-	Tumour <10cm in 28/40	-	-
Lahon	157/157 (100%)	Likely all	-	67/157 (43%)	9 ^(MD)	0.3 – 30	England (1989)
Liu	21/21 (100%)	100%	All surgical margins clear	3/21 (14.3%)	6.5 ^(MD)	4.0 – 18.5	England (1989)
McGuire	23/26 (88.5%)	100%	-	8/23 (34.8%)	9.1 ^(MN)	-	England (1989)
O'Neil	-	-	-	18/49 (37%)	-	-	Hypercellular and mitotically active (≥ 4 mitoses per 10 HPF)
Rena	21/21 (100%)	100%	-	8/21 (38%)	-	2.2 – 33	-
Santos	34/34 (100%)	100%	-	7/34 (21%)	7.2 ^(MN)	1.2 – 24	England (1989)
Schmid	22/25 (88%)	20/22 (91%)	R1 – bSFTP(1), mSFTP(1) No recurrence	8/25 (32%)	11.6 ^(MN)	2 – 25	World Health Organisation (2013)
Tan	82/82 (100%)	-	-	12/82 (14.6%)	bSFTP 8.89 ^(MN) mSFTP 13.79 ^(MN)	-	England (1989)
Tapias	59/59 (100%)	100%	All R0	-	7.3 ^(MN) \pm 6.7 ^(SD) 5 ^(MD)	0.7 – 33	-
Vejvodova	20/22 (90.9%)	-	-	4/22 (18.2%)	-	3 – 30	>4 mitosis/2mm ²
Yeom	33/41 (80.5%)	-	-	6/41 (14.6%)	6 ^(MD)	1 – 17	England (1989)

*bSFTP – benign solitary fibrous tumour of the pleura, mSFTP – malignant solitary fibrous tumour of the pleura, MD – median, MN – mean, SD – standard deviation, HPF – high powered field, R0 – all resection margins clear, R1 – microscopic positive margins, R2 grossly positive margins
England (1989) criteria - One or more of: increasing mitotic activity (>4 mitoses/ 10 HPF); high cellularity with crowding and overlapping of nuclei; presence of necrosis; and pleomorphism